The 30th International Society for Prenatal Diagnosis (ISPD) Conference 2026

Published: 24 June 2026

Details:

Gene Solutions is proud to join the 30th International Conference on Prenatal Diagnosis and Therapy, ISPD 2026, as a Premier Partner.

ISPD is a global scientific platform bringing together clinicians, researchers, geneticists, fetal medicine specialists, and healthcare innovators to advance the future of reproductive and prenatal healthcare. 

At this landmark global conference, Gene Solutions will contribute to the scientific exchange through: 

1. An Industry Symposium on integrated non-invasive prenatal testing, expanded carrier screening, single-gene disorders, and AI-enabled pregnancy risk stratification. 

Advancing Prenatal Screening: Validation and Clinical Utility of Integrated Non-Invasive Testing with Focus on Carrier Screening and Single-Gene Disorders 

Time: 7:30 – 8:30 (EDT), 8 July 2026 

2. An Industry Scientific Session on methylation-based endometrial cancer triage, featuring clinical validation and real-world application of epiHERA®.  

Minimally Invasive Endometrial Cancer Triage Using Methylation to Reduce Unnecessary Dilation and Curettage/Biopsies in Transvaginal Ultrasound High-Risk Patients 

Time: 7:30 – 8:00 (EDT), 9 July 2026 

3. Five selected oral and poster presentations from Gene Solutions and Medical Genetics Institute Ho Chi Minh City, demonstrating real-world evidence in prenatal genomics. 

2 Oral presentations | 7 July 2026, 13:00 – 14:00 (EDT) 

Presenting real-world evidence on expanded carrier screening and clinical exome sequencing, highlighting advances in prenatal genomic testing and maternal-fetal medicine. 

3 Virtual Posters | 8 July 2026, 13:30 – 14:15 (EDT) 

Showcasing research on thalassemia screening, NIPT clinical performance, and prenatal chromosomal abnormalities, contributing to the evidence base for genomic applications in prenatal care. 

 

Together, these contributions spotlight two important frontiers in reproductive health: next-generation NIPT and methylation-based gynecologic cancer risk assessment, anchored by innovations including triSure Procare, epiHERA®, and SPOT-MAS Eva. 

As prenatal and women’s healthcare move toward more comprehensive, personalized, and minimally invasive approaches, Gene Solutions remains committed to translating genomic and epigenomic science into meaningful clinical solutions. 

 

Save the date and join us at ISPD 2026.  

🔗 Read the full news: https://genesolutions.com/news/gene-solutions-contributes-latest-prenatal-genomics-findings-and-womens-health-research-at-ispd-2026/

🔗 Learn more about ISPD 2026: https://ispd2026.eventscribe.net/ 
🔗 Discover triSure Procare: https://genesolutions.com/our-test/trisure-procare 

🔗 Discover SPOT-MAS Eva: https://genesolutions.com/news/gene-solutions-expands-spot-mas-portfolio-with-accessible-cancer-screening-and-precision-triage-solutions